IMDC Risk Model for Metastatic RCC

The IMDC risk model stratifies metastatic renal cell carcinoma patients into favorable, intermediate, or poor prognostic groups based on six clinical and laboratory factors.

< 1 year from time of diagnosis to systemic therapy
No0Yes+1
Karnofsky Performance Status < 80%
No0Yes+1
Hemoglobin < lower limit of normal
No0Yes+1
Corrected calcium > upper limit of normal
No0Yes+1
Neutrophils > upper limit of normal
No0Yes+1
Platelets > upper limit of normal
No0Yes+1

Indications for Use

Used for adults with metastatic RCC before starting systemic therapy to stratify prognosis into favorable, intermediate, or poor risk, guiding first‑line regimen selection, counseling on expected survival, and clinical‑trial stratification per ESMO/NCCN [1](https://doi.org/10.1016/j.annonc.2024.05.537\) [Level I evidence]; [2](https://doi.org/10.6004/jnccn.2022.0001\) [Level I evidence]. Continues to discriminate outcomes even with modern IO‑based combinations [3](https://doi.org/10.1016/j.eururo.2023.01.001\) [Level II evidence].

Insights & Cautions

Assigns prognosis for metastatic RCC using six adverse factors (KPS <80%, low hemoglobin, high calcium, neutrophilia, thrombocytosis, diagnosis‑to‑treatment <1 year). Strongly validated across VEGFR‑TKI and ICI eras with consistent discrimination (C‑index ~0.66) and survival separation 1 [Level II evidence]. Use cautiously: derived in targeted‑therapy era, less predictive for ICI response 2 [Level I evidence], and does not account for metastatic pattern or molecular features.